Literature DB >> 8335524

The mouse peritonitis model: present and future use.

N Frimodt-Møller1.   

Abstract

The mouse peritonitis model was the first experimental animal model to be used in antibiotic research in 1935, where it proved the effect of Prontosil and derivative sulphonamides against Streptococcus pyogenes in vivo. Since then the mouse peritonitis model has been a natural step in testing antibiotics in vivo before moving to larger animals or humans. Only a few bacteria are naturally virulent to mice, e.g. Streptococcus pneumoniae, but the mice can be rendered susceptible to most human pathogens by inhibition of one or more parts of the natural defence of the animals. For measuring the effect of antibiotics two parameters are usually considered: bacterial counts in fluids or tissues, or death/survival of the animal. Both parameters have flaws, but death is usually used, owing to the ease of observation and quantification by calculation of the 50% effective (protective or curative) doses. With these parameters a number of significant factors of importance for antibiotic effect have been detected or proven in this model. Together with the recent insight into the correlation of pharmacokinetic behaviour between these small animals and man, it is predicted that the mouse peritonitis model will continue to be an important means of studying the effect of antibiotics in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335524     DOI: 10.1093/jac/31.suppl_d.55

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.

Authors:  Matilde Gracia; Carmina Martínez-Marín; Lorena Huelves; Maria J Giménez; Lorenzo Aguilar; Antonio Carcas; Carmen Ponte; Francisco Soriano
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 4.  The role of CRISPR-Cas systems in virulence of pathogenic bacteria.

Authors:  Rogier Louwen; Raymond H J Staals; Hubert P Endtz; Peter van Baarlen; John van der Oost
Journal:  Microbiol Mol Biol Rev       Date:  2014-03       Impact factor: 11.056

5.  Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis.

Authors:  A Wellmer; J Gerber; J Ragheb; G Zysk; T Kunst; A Smirnov; W Brück; R Nau
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.

Authors:  Anne Sandberg; Klaus Skovbo Jensen; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

7.  Large-scale identification of genes required for full virulence of Staphylococcus aureus.

Authors:  Bret M Benton; J P Zhang; Skip Bond; Casey Pope; Todd Christian; Lawrence Lee; Kelly M Winterberg; Molly B Schmid; Jerry M Buysse
Journal:  J Bacteriol       Date:  2004-12       Impact factor: 3.490

8.  Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.

Authors:  Karoline Sidelmann Brinch; Anne Sandberg; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

9.  Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics.

Authors:  Karoline Sidelmann Brinch; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

10.  Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model.

Authors:  J Yuste; I Jado; M J Giménez; L Aguilar; F Molero; A Fenoll; J Casal
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.